ERK inhib 
Welcome,         Profile    Billing    Logout  
 15 Companies  10 Products   10 Products   27 Diseases   106 Trials   1784 News 
151 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Triolex (bezisterim) / BioVie
NCT04669028: A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

Completed
3
439
US
NE3107, Placebo
BioVie Inc.
Alzheimer Disease
09/23
10/23
NCT05970575: Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

Recruiting
2
5
US
NE3107
Neurological Associates of West Los Angeles, BioVie Inc.
Traumatic Brain Injury
12/24
07/25
NCT05083260: NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

Completed
1/2
46
US
NE3107, placebo
BioVie Inc.
Parkinson Disease
11/22
01/23
Rydapt (midostaurin) / Novartis
RATIFY, NCT00651261 / 2006-006852-37: Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Checkmark AML patients with FLT3 mutations
Dec 2015 - Dec 2015: AML patients with FLT3 mutations
Checkmark RATIFY trial for AML with FLT3 mutations at ASH 2015
Dec 2015 - Dec 2015: RATIFY trial for AML with FLT3 mutations at ASH 2015
Checkmark RATIFY trial in AML
More
Active, not recruiting
3
717
Canada, US
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Novartis Pharmaceuticals
Leukemia
07/16
 
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting
3
510
US
Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin
Arog Pharmaceuticals, Inc.
Newly Diagnosed FLT3 Mutated AML
11/22
11/24
AMELIORATE, NCT04174612: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting
3
172
Europe
Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia With FLT3/ITD Mutation
12/22
08/25
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
12/24
06/33
NCT03092674: Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Active, not recruiting
2/3
76
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Laboratory Biomarker Analysis, Midostaurin, CGP 41251, CGP41251, N-Benzoyl-Staurosporine, N-Benzoylstaurosporine, PKC 412, PKC-412, PKC412, Rydapt, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
08/23
10/24
2017-002094-18: Prospective evaluation of a continuation therapy with Midostaurin in adult patients withcore-binding factor leukemia and integrated genetic analysis: a multi-center phase II study Studio multicentrico di fase II. Valutazione prospettica di una terapia continuativa con Midostaurina in pazienti adulti con leucemia mieloide acuta "core-binding factor"

Ongoing
2
39
Europe
Midostaurina, [PKC412], Capsule, soft
AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA, Novartis x midostaurina
Acute Myeloid Leukemia (AML) Leucemia Mieloide Acuta, Acute Myeloid Leukemia (AML) Leucemia Mieloide Acuta, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03280030: A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Hourglass Jul 2021 - Dec 2021 : Final data from trial for newly diagnosed patients with FLT3-mutated AML
Completed
2
75
Japan, RoW
Midostaurin, PKC412, Placebo
Novartis Pharmaceuticals
Acute Myeloid Leukemia
03/20
11/22
HO155, NCT04097470 / 2018-000047-31: Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Active, not recruiting
2
140
Europe
Decitabine, Dacogen, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Swiss Group for Clinical Cancer Research
AML/MDS
11/21
11/26
AML FLT3, NCT03686345 / 2017-002094-18: Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia

Recruiting
2
39
Europe
Midostaurin
Niguarda Hospital, Novartis x midostaurina
Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
06/23
12/25
PrE0905, NCT03836209: Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Active, not recruiting
2
181
US
Gilteritinib, ASP2215, Midostaurin, RYDAPT, Daunorubicin, Daunorubicin hydrochloride, Daunomycin, Rubidomycin, Cerubidine, Cytarabine, Cytosar-U, Ara-C, Arabinosyl, Cytosine Arabinoside
PrECOG, LLC., Astellas Pharma Inc
Acute Myeloid Leukemia
10/23
12/24
P30CA036727, NCT03226418: Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Completed
2
75
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Decitabine, 5-Aza-2'-deoxycytidine, Aza-TdC, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Idarubicin, 4-Demethoxydaunomycin, 4-demethoxydaunorubicin, 4-DMDR, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Azacitidine, VIDAZA, Venetoclax, Venclexta, Venclyxto, glasdegib, Daurismo
University of Nebraska, National Cancer Institute (NCI)
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
03/24
10/24
NCI-2014-01103, NCT02115295: Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Recruiting
2
508
US
Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Gilteritinib, ASP-2215, ASP2215, Xospata, Idarubicin, 4-Demethoxydaunomycin, 4-demethoxydaunorubicin, 4-DMDR, Laboratory Biomarker Analysis, Midostaurin, CGP 41251, CGP41251, N-Benzoyl-Staurosporine, N-Benzoylstaurosporine, PKC-412, PKC412, Rydapt, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
05/25
05/26
NCT03591510 / 2017-004830-28: A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Calendar Jan 2025 - Dec 2025: Data from trial in newly diagnosed pediatric patients with FLT3-mutated acute AML
Recruiting
2
23
Europe, Japan, US, RoW
Midostaurin, PKC412, Fludarabine, Part 1 Block 2 induction FLADx, Cytarabine, Part 1:, Block 2 induction FLADx, Block 3 consolidation HAM, Block 4 consolidation HA3E, Block 5 consolidation HIDAC, Part 2:, Block 2 induction HAM, Block 3 consolidation HA3E, Block 4 consolidation HAM, Daunorubicin or idarubicin, Mitoxantrone, Etoposide
Novartis Pharmaceuticals
FLT3-mutated Acute Myeloid Leukemia
08/25
02/29
DEXAML-02, NCT03609060: Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)

Active, not recruiting
2
120
Europe
Dexamethasone
French Innovative Leukemia Organisation
Acute Myeloid Leukemia
08/25
12/25
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Active, not recruiting
2
107
US
Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology
Acute Myeloid Leukemia
07/29
07/29
2017-002335-42: A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation . Onderzoek naar de behandeling van patiënten met een specifiek type AML, met de middelen panobinstat en midostaurin gedurende 1 jaar na donor-stamceltransplantatie.

Ongoing
1/2
40
Europe
panobinostat, Midostaurin, Capsule, Farydak 20 mg, Rydapt
HOVON Foundation, Novartis
adverse risk AML or RAEB, 'High risk' acute myeloid leukemia of myedysplastic syndrome, Diseases [C] - Cancer [C04]
 
 
MOSAIC, NCT04385290 / 2019-003863-23: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia

Recruiting
1/2
214
Europe
MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin
Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer
Acute Myeloid Leukemia
04/27
04/28
NCT04982354: Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Withdrawn
1/2
20
US
CPX-351, Midostaurin, Rydapt, Busulfan, Myleran, Melphalan, Alkeran, Fludarabine, Fludara, CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor
Guenther Koehne, Jazz Pharmaceuticals
Acute Myeloid Leukemia
08/31
08/32
V-FAST master, NCT04075747: A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

Completed
1b
57
US
CPX-351, Vyxeos, JZP351, Venetoclax, Venclexta, Midostaurin, Rydapt, Enasidenib, Idhifa
Jazz Pharmaceuticals
Acute Myeloid Leukemia
02/22
09/23
NCT00819546: RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Checkmark P1 data - ASH 2012
Nov 2012 - Nov 2012: P1 data - ASH 2012
Active, not recruiting
1
29
US
RAD001, everolimus, PKC412, midostaurin
Richard Stone, MD, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Novartis
Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/25
12/25
NCI-2019-01726, NCT03900949: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Recruiting
1
18
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Midostaurin, CGP 41251, CGP41251, N-Benzoyl-Staurosporine, N-Benzoylstaurosporine, PKC-412, PKC412, Rydapt
Uma Borate
Acute Myeloid Leukemia
01/25
01/25
AML-VAC-XS15, NCT06252584: Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

Not yet recruiting
1
20
NA
Vaccines, Peptide, Multipeptide Vaccine AML-VAC-XS15
University Hospital Tuebingen
Acute Myeloid Leukemia, Adult
05/26
11/26
NCT06313437: Revumenib in Combination With 7+3 + Midostaurin in AML

Not yet recruiting
1
22
US
Revumenib, SNDX-5613, Trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2- yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide, Midostaurin, Rydapt, Cytarabine, cytosine arabinoside (ara-C), Daunorubicin, Daunomycin
Maximilian Stahl, MD, Syndax Pharmaceuticals
Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
03/26
03/27
NCT03114228: An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

No Longer Available
N/A
Canada
Midostaurin
Novartis Pharmaceuticals
FLT3-mutated Acute Myeloid Leukemia
 
 
AMLFLT3, NCT02624570: Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

No Longer Available
N/A
US
Midostaurin, PKC412
Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
 
 
NCT05219266: Managed Access Programs for PKC412, Midostaurin

No Longer Available
N/A
NA
midostaurin, PKC412
Novartis Pharmaceuticals
FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia, Acute Myeloid Leukemia, Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis With an Associated Hematologic Neoplasm
 
 
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
DYNHAEMICS, NCT05304156: Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"

Recruiting
N/A
200
Europe
Biobanking blood and bone marrow specimens
Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
04/26
05/26
dordaviprone (ONC201) / Chimerix
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
BIOMEDE 2, NCT05476939: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Recruiting
3
409
Europe
Everolimus, VOTUBIA, AFINITOR, ONC201, Radiotherapy
Gustave Roussy, Cancer Campus, Grand Paris, Chimerix, Innovative Therapies For Children with Cancer Consortium, Ministry of Health, France
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
09/28
09/31
NCT03485729: ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Active, not recruiting
2
30
US
ONC201
Chimerix
Endometrial Cancer Recurrent
12/22
12/22
NCT02525692: Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma

Checkmark Efficacy and safety data from trial for midline diffuse glioma
Jan 2022 - Jan 2022: Efficacy and safety data from trial for midline diffuse glioma
Active, not recruiting
2
89
US
ONC201
Chimerix
Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma
08/23
12/23
NCT03295396: ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Active, not recruiting
2
95
US
ONC201
Chimerix
Glioma
08/23
09/23
NCT04629209: A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Withdrawn
2
36
US
ONC201
Masonic Cancer Center, University of Minnesota, University of Minnesota
Glioblastoma
12/24
06/25
NCT04055649: ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recruiting
2
62
US
Akt/ERK Inhibitor ONC201, ONC201, TIC10, Paclitaxel, Ester, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Alpha, Beta, Questionnaire Administration
Ira Winer
Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
05/25
05/26
NCT05009992: Combination Therapy for the Treatment of Diffuse Midline Gliomas

Hourglass Jun 2024 - Jul 2024 : Follow up data for DMG
Recruiting
2
360
Europe, US, RoW
ONC201, TIC10, Antagonist of dopamine receptor D2 (DRD2) and caseinolytic protease proteolytic subunit (ClpP), Radiation Therapy, Radiotherapy, Paxalisib, Inhibitor of the PI3K/AKT/mTOR pathway, GDC-0084, GDC0084, PI3K Inhibitor GDC-0084
University of California, San Francisco, The Chad-Tough Defeat DIPG Foundation, Mithil Prasad Foundation, Storm the Heavens Fund, National Institute of Neurological Disorders and Stroke (NINDS)
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
12/25
06/29
NCT06012929: A Study of ONC201 for Refractory Meningioma

Not yet recruiting
2
27
US
ONC201, dordaviprone
University of Nebraska, Chimerix
Meningioma, Refractory Meningioma, Relapsed Meningioma
04/26
04/27
NCT02863991: Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Terminated
1/2
17
US
ONC201, Dexamethasone
Chimerix, Oncoceutics, Inc.
Multiple Myeloma
09/19
12/19
NCT02392572: ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting
1/2
120
US
Akt/ERK Inhibitor ONC201, ONC-201, ONC201, TIC10
M.D. Anderson Cancer Center, Oncoceutics, Inc.
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
11/26
11/26
ACTRN12622000405718p: Effect of ONC201 on participants with renal impairment

Not yet recruiting
1
16
 
Chimerix, Inc., Chimerix, Inc.
Cancer; Solid Tumours; Renal Impairment
 
 
ACTRN12621001002875: Investigating the safety and tolerability of ONC201 in healthy adults - Part A

Completed
1
15
 
Chimerix, Inc., Chimerix, Inc.
Cancer
 
 
ACTRN12621000975897: Investigating the safety and tolerability of ONC201 in healthy adults under fasting and fed conditions

Completed
1
18
 
Chimerix, Inc., Chimerix, Inc.
Cancer
 
 
ACTRN12621001003864: Investigating the safety and tolerability of ONC201 in healthy adults under fasting and fed conditions - Part 2b

Completed
1
30
 
Chimerix, Inc., Chimerix, Inc.
Cancer
 
 
ACTRN12622001021763: Effect of ONC201 on Cardiac Repolarization in Healthy Participants - Part 1

Completed
1
6
 
Chimerix, Inc., Chimerix, Inc.
Cancer, Solid Tumours, Abnormal cardiac repolarization
 
 
ACTRN12622001020774: Effect of ONC201 on Cardiac Repolarization in Healthy Participants - Part 2

Completed
1
30
 
Chimerix, Inc., Chimerix, Inc.
Cancer, Solid Tumours, Abnormal cardiac repolarization
 
 
ACTRN12622000405718: Effect of ONC201 on participants with renal impairment

Completed
1
16
 
Chimerix, Inc., Chimerix, Inc.
Cancer, Solid Tumours, Renal Impairment
 
 
ONC014, NCT03416530: ONC201 in Pediatric H3 K27M Gliomas

Active, not recruiting
1
130
US
ONC201
Chimerix
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
08/23
09/23
NCT03932643: ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

Active, not recruiting
1
20
US
ONC-201, dordaviprone
University of Nebraska
Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/26
08/27
NCT05542407: ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Recruiting
1
58
US
Atezolizumab, ONC201
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc., Oncoceutics, Inc.
Endometrial Cancer, Metastasis
01/25
07/25
NCT05630794: Testing ONC201 to Prevent Colorectal Cancer

Not yet recruiting
1
24
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Colonoscopy, Dordaviprone, Akt/ERK Inhibitor ONC201, ONC201, TIC10, Questionnaire Administration, Sigmoidoscopy, Proctosigmoidoscopy
National Cancer Institute (NCI)
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
01/26
01/28
NCT03134131: Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

No Longer Available
N/A
US
ONC201
Chimerix
Glioma
 
 
NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Available
N/A
US
ONC201 (dordaviprone)
Chimerix
Glioma, H3 K27M
 
 
NCT05392374: Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

No Longer Available
N/A
US
ONC201
Chimerix
Glioma
 
 
luxeptinib (CG-806) / Aptose Biosci
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Active, not recruiting
1
160
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
12/24
05/25
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Active, not recruiting
1
80
US
CG-806
Aptose Biosciences Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
05/25
Zepsun (donafenib) / Suzhou Zelgen
ChiCTR2100054041: Efficacy and safety of donafenib combined with TACE or HAIC in the treatment of hepatocellular carcinoma

Recruiting
4
50
 
No
Shandong Cancer Hospital; Shandong Cancer Hospital, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2100053712: Clinical study of the efficacy and safety of donafenib plus S-1 in first-line treatment of metastatic pancreatic cancer that failed NG(nab-Paclitaxel plus Gemcitabine) regimen

Recruiting
4
10
 
Donafenib, Teggio
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, self-funded
pancreatic cancer
 
 
NCT05022628: Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis

Not yet recruiting
4
30
NA
Donafenib, Radiotherapy
Anhui Provincial Hospital
HCC, Chemotherapy Effect
08/23
08/24
ChiCTR2100050060: Clinical study on the safety and efficacy of donafenib tosylate combined with toripalimab injection in first-line/second-line treatment of patients with advanced biliary tract cancer who refuse chemotherapy

Not yet recruiting
4
36
China
Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV ;Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences ; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, self-raised
Biliary tract cancer
 
 
ChiCTR2100050061: Clinical study on the safety and efficacy of donafenib tosylate combined with camrelizumab in the first-line/second-line treatment of patients with advanced hepatocellular carcinoma

Not yet recruiting
4
36
 
Donafenib Tosylate Tablets Combined with Camrelizumab ;Donafenib Tosylate Tablets Combined with Camrelizumab
Peking Union Medical College Hospital; Chinese Academy of Medical Sciences Peking Union Medical College Hospital, self-raised
Hepatocellular carcinoma
 
 
ChiCTR2100052129: A single-arm, open-ended study on the efficacy and safety of donafenib combined with temozolomide and radiotherapy in the treatment of postoperative patients with high-grade glioma

Not yet recruiting
4
10
 
Donafenib, 200 mg BID po; temozolomide, 75 mg/m2·d; concurrent radiotherapy
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-raised
Hepatocellular carcinoma
 
 
ChiCTR2200057124: Clinical study on the efficacy and safety of donafenib toluenesulfate tablets combined with TACE in the treatment of early and middle stage hepatocellular carcinoma not suitable for surgical resection

Not yet recruiting
4
38
 
Donafenib combined with TACE
Beijing You'an Hospital, Capital Medical University; Beijing You'an Hospital, Capital Medical University, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2200056206: Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Donafenib and Sintilimab in the treatment of patients with unresectable hepatocellular carcinoma: a single-arm, exploratory clinical study

Not yet recruiting
4
41
 
HAIC and Donafinil 0.1g, bid and Sintilimab 200mg, Q3w
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology; Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, self-raised
Hepatocellular carcinoma
 
 
ChiCTR2200058747: Efficacy and safety of Donafenib combined with camrelizumab + TACE in the first-line treatment of advanced HCC

Not yet recruiting
4
30
 
Donafenib combined with camrelizumab + TACE
Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
Hepatocellular Carcinoma
 
 
ChiCTR2200059297: The safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) + donafenib + PD-1 antibody in the conversion-resection of advanced unresectable hepatocellular carcinoma: Observational Real World Study.

Not yet recruiting
4
30
 
Nil
The Fifth Medical Center of PLA General Hospital; The Fifth Medical Center of PLA General Hospital, Self-fund
Hepatocellular carcinoma
 
 
NCT05673824: Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.

Recruiting
4
53
RoW
Huaier Granule, VEGFR-TKIs
Fudan University, LinkDoc Technology (Beijing) Co. Ltd.
Nephrotoxicity
02/25
04/25
ChiCTR2100050053: The efficacy and safety of Donafenib combined with TACE in the treatment of advanced hepatocellular carcinoma

Not yet recruiting
4
30
 
donafeinib+TACE
Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University, self-financed
Hepatocellular carcinoma
 
 
NCT06496815: Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

Not yet recruiting
4
32
NA
Donafenib, transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy, PD-1,PD-L1
Tongji Hospital
Unresectable Hepatocellular Carcinoma
08/26
07/27
ChiCTR2100049493: Donafenib and Toripalimab in combination with transarterial chemoembolization and bronchial arterial chemoinfusion Versus Donafenib and Toripalimab in the treatment of hepatocellular carcinoma with pulmonary metastasis: a randomized controlled trial

Not yet recruiting
4
130
China
TACE、BAI combined with donafinib and triprizumab ;donafinib and triprizumab
Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital ; Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2100050662: A single-arm, open-label clinical study of donafenib combined with sintilimab for unresectable hepatocellular carcinoma

Not yet recruiting
4
30
 
Donafinil and Sintilimab
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2100051171: Safety and efficacy of Donafenib combined with PD -1/PD-L1 inhibitors in primary/second-line treatment of patients with advanced hepatocellular carcinoma

Recruiting
4
50
 
combination of anti-pd-1 / pd-l1 antibody and Donafenib ;combination of anti-pd-1 / pd-l1 antibody and Donafenib
Department of Hepatobiliary Surgery Chinese PLA General Hospital & Medical School; Chinese PLA General Hospital & Medical School, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2200063822: A Multicenter Registration Study to Evaluate the Efficacy and Safety of Donafenib as 1st line treatment in patients with unresectable HCC

Not yet recruiting
4
200
 
Donafenib
Sun Yat-sen memorial hospital Sun Yat-sen university; Sun Yat-sen memorial hospital Sun Yat-sen university, self-raised funds
hepatocellular carcinoma
 
 
HOPE-a, ChiCTR2200064030: A Multicenter Registration Study to Evaluate the Efficacy and Safety of Donafenib in Patients with HCC as Adjuvant Treatments for Hepatocellular Carcinoma After Radical Resection

Recruiting
4
200
 
Donafenib
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, self-raised
hepatocellular carcinoma
 
 
ChiCTR2100052000: Clinical study on the efficacy and safety of donafenib toluenesulfonic tablets combined with argon and helium cryoablation and camrelizumab injection in the treatment of middle and advanced hepatocellular carcinoma unsuitable for surgery

Not yet recruiting
4
30
 
Donafenib toluenesulfonic tablets, 200 mg BID po; camrelizumab, 3 mg/kg Q3W iv; cryoablation
The Fifth Medical Centre of the General Hospital of PLA; The Fifth Medical Centre of the General Hospital of PLA, self-raised
Hepatocellular carcinoma
 
 
NCT06685289: Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Not yet recruiting
4
70
NA
Donafenib, capecitabine
The First Affiliated Hospital with Nanjing Medical University
Biliary Malignant Tumors
11/26
11/27
ChiCTR2200059858: A single arm, real world stuy for the effectiveness and safety of HAIC combined with Donafenib Toslate Tablets and Sindilimab Injection in the prophylactic treatment of MVI positive patients‘ recurrence after radical resection of hepatocelluar carcinoma

Not yet recruiting
4
30
 
HAIC combined with Donafenib Toslate Tablets and Sindilimab Injection
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Self-raised
Hepatocelluar carcinoma
 
 
ChiCTR2300075973: The Efficacy and Safety of Donafenib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: a Phase II Clinical Trial

Not yet recruiting
4
13
 
donafenib
Fujian Cancer Hospital; Fujian Cancer Hospital, Self-fund
differentiated thyroid cancer
 
 
ChiCTR2300074183: Neoadjuvant donafenib and anti-PD-1antibody ± hepatic arterial infusion chemotherapy for resectable hepatocellular carcinoma with high recurrence risks: real-world research

Not yet recruiting
4
104
 
donafenib＋PD-1±HAIC for perioperative period (preoperative neoadjuvant + postoperative adjuvant); donafenib＋PD-1 for postoperative adjuvant
The General Hospital of the People's Liberation Army; The General Hospital of the People's Liberation Army, self-fund
Hepatocellular carcinoma
 
 
ChiCTR2300076242: Canceled by the investigator. Clinical study on the first-line treatment of advanced hepatocellular carcinoma with B-grade liver function using lenvatinib combined with sintilimab and compared to donafenib combined with sintilimab

Not yet recruiting
3
148
 
lenvatinib combined with sintilimab; Donafenib combined with sintilimab
Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, investigator initiated trial (IIT)
hepatocellular carcinoma
 
 
Neo-TACE, NCT05171166: Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Recruiting
2/3
156
RoW
HAIC, TACE, FOLFOX, oxaliplatin, leucovorin, 5-fluorouracil, cTACE or DEB-TACE, EPI, Donafenib, Dona
Peking University
Hepatocellular Carcinoma
06/24
12/24
ChiCTR2400090460: An open, single-arm, multicenter, prospective clinical study of the efficacy and safety of Donafenil tosylate combined with Sindilizumab in the adjuvant treatment of patients with hepatocellular carcinoma at high risk of recurrence after surgery

Not yet recruiting
2/3
52
 
Sindilizumab (200mg, iv, Q3W) combined with Donafenib 100mg, po, bid
Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital horizontal research project
Hepatocellular Carcinoma
 
 
NCT06482086: Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting
2
75
RoW
Anlotinib, Lenvatinib, Sorafenib, Donafenib, Everolimus, Apatinib, Dabrafenib + Trametinib, Cabozantinib, Vandetanib, Entrectinib, Pralsetinib, Larotrectinib
West China Hospital
Locally Advanced Thyroid Gland Carcinoma
12/24
12/25
FRONT-2, NCT06232759: TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Completed
2
56
RoW
Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
Guangxi Medical University
Hepatocellular Carcinoma
10/23
01/24
NCT05350943: HAIC Combined With Toripalimab and Donafenib for Advanced BTC

Enrolling by invitation
2
70
RoW
HAIC, Gemcitabine, Oxaliplatin, Toripalimab, Donafenib
Lu Wang, MD, PhD
Biliary Tract Adenocarcinoma
11/22
11/23
NCT05162352: Donafenib Plus Sintilimab for Advanced HCC

Recruiting
2
30
RoW
Donafenib+sintilimab
Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
05/23
05/23
NCT05138159: A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Not yet recruiting
2
10
RoW
Donafenib, S1
Fudan University
Metastatic Pancreatic Cancer
05/23
07/23
NCT05348811: HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Recruiting
2
32
RoW
HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab
Zhongda Hospital
Cholangiocarcinoma
06/23
07/23
NCT05493332: HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

Not yet recruiting
2
93
NA
HAIC(FOLFOX), Hepatic Artery Infusion Chemotherapy, FOLFOX, Oxaliplatin, Leucovorin, Fluorouracil, Toripalimab, Donafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
09/23
09/24
ChiCTR2100051714: HAIC combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus (PVTT) invasion into the main portal vein: a single-arm, exploratory clinical study

Not yet recruiting
2
32
 
HAIC(hepatic arterial infusion chemotherapy), donafinil and carrelizumab
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Hepatocellular carcinoma
 
 
NCT05545124: Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Not yet recruiting
2
32
NA
Donafenib + Tislelizumab
Henan Cancer Hospital
Hepatocellular Carcinoma
11/23
11/24
ChiCTR2100044790: A Clinical Study of the Effcacy and Safety of Donafenib Combined with Toripalimab in the Second-Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer

Recruiting
2
61
China
Donafenib Combined with Toripalimab; Donafenib Combined with Toripalimab
Chinese PLA General Hospital ; Chinese PLA General Hospital, self funded
SCLC
 
 
NCT05161143: Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma

Not yet recruiting
2
30
RoW
Donafenib, TACE
Peking Union Medical College Hospital, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hepatocellular Carcinoma
12/23
12/24
DoHAICs, NCT05166772: Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Not yet recruiting
2
30
NA
Donafenib, Sintilimab, HAIC
Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
12/23
12/24
NCT05310331: Donafenib for Recurrent Cervical Cancer

Recruiting
2
20
RoW
Donafenib combined with paclitaxel and platinum ± PD-1 antibody
Lei Li
Targeted Therapy, Chemotherapy, Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Survival Outcomes, Adverse Effect
12/23
06/24
NCT06244225: HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Recruiting
2
38
RoW
Donafenib； Sintilimab； HAIC
Wuhan Union Hospital, China
Hepatocellular Carcinoma
01/26
01/28
NCT04962958: Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Not yet recruiting
2
30
RoW
Hepatic arterial infusion chemotherapy, HAIC, Folfox Protocol, Oxaliplatin , fluorouracil, and leucovorin, Donafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Huashan Hospital, The Second Affiliated Hospital of Harbin Medical University
Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms, Antineoplastic Agents, Donafenib, Fluorouracil, Oxaliplatin, Antimetabolites
03/24
08/24
NCT05262959: A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

Completed
2
30
RoW
Donafenib, PD-1, TACE
Shanghai Zhongshan Hospital
Donafenib
04/24
05/24
 

Download Options